Proffered Paper - CNS Tumours
LINK to Proffered Paper - CNS Tumours
360O - Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
The abstract concludes: Analysis of two independent cohorts of glioblastoma patients, including the prospective GGN cohort, did not confirm previous data suggesting that TERT promoter mutations confer an enhanced benefit from TMZ in patients with MGMT promoter-methylated glioblastoma. Thus, diagnostic testing for TERT promoter mutations may not be required for prediction of TMZ sensitivity in IDH-wildtype glioblastoma patients.
361O - Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study
The abstract concludes: This study represents one of the largest trials analyzing MGMTmet by pyrosequencing approach. Lower values of MGMTmet were associated with impaired survival and the relationship was non-linear. Noteworthy, we identified a strong prognostic value of MGMTmet which could be used as stratification factor in prospective clinical trials.
362O - Perifocal edema volume correlates with density of tumour-infiltrating cytotoxic T cells in newly diagnosed glioblastoma
The abstract concludes: Peritumoral non-enhancing T2-hyperintense signal abnormality volumes correlate with the density of intra-tumoral cytotoxic T cells in newly diagnosed glioblastoma and may serve as “immuno-radiomic” surrogate parameter.
363O - Clinical characterization of a real-life cohort of 6001 patients with brain metastases from solid cancers treated between 1986-2020
The abstract concludes: For BM patients, treatment patterns have changed towards increased use of SRS as well as systemic therapies, and survival times have improved over time. Furthermore, our data confirm refinement of BM-specific prognostic scores by incorporation of molecular data.
364O - Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
The abstract concludes: Entrectinib shows durable IC activity in pts with NTRK-fp solid tumours and baseline CNS metastases.